Traditional MedicareCoverageMedium impact
Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea
Medicare/CMS - LCD·Sleep Medicine, Neurology, Pulmonology·Local Coverage Determination
Effective date
Apr 1, 2026
We identified it
Jul 28, 2026
Summary
Wellpoint Federal has updated Local Coverage Determination L38387 to establish coverage policy for hypoglossal nerve stimulation (HGNS) as a treatment for obstructive sleep apnea. This policy, effective April 1, 2026, applies to both Medicare Part A and Part B claims and will require billing and clinical teams to understand coverage criteria, medical necessity documentation, and applicable procedure codes for this device-based therapy.
Action Required
By March 15, 2026: Obtain full policy details from the CMS Medicare Coverage Database (URL provided) to identify specific CPT/HCPCS codes, prior authorization requirements, and medical necessity criteria for hypoglossal nerve stimulation procedures. Billing team and clinical staff must: (1) Review coverage requirements and patient eligibility criteria; (2) Determine if prior authorization is required before procedure scheduling; (3) Update billing system and encounter documentation templates to capture required clinical information (e.g., OSA severity, failed conservative treatments); (4) Train providers on documentation standards for medical necessity; (5) Coordinate with Wellpoint Federal for any credentialing or claim submission process changes. Failure to comply with coverage criteria will result in claim denials. NOTE: The policy summary provided does not include specific procedure codes — access the full CMS LCD document immediately to identify exact billable codes and coverage parameters.